Clarifying the Vascular Aspects of Dementia

Completed

Conditions: hersenaandoening
Alzheimer's disease
dementia
10047075

Registration Number: NL-OMON55875

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 280

Inclusion Criteria

Patients who attended the memory clinic of the Leiden University Medical
Center/ Bronovo/ Reinier de Graaf hospital within one year ago
• Diagnosed with probable Alzheimer's disease
• Diagnosed as Mild cognitive impairment
• Diagnosed as Subjective cognitive impairment
• Diagnosed as Vascular dementia
• Capable of giving informed consent (see appendix)Control subjects
• Healthy adults without memory complaints aged between 40-90 years old
t>üâ

Exclusion Criteria

- Contra-indication to MRI scanning:
• Claustrophobia
• Pacemakers and defibrillators
• Nerve stimulators
• Intracranial clips
• Intraorbital or intraocular metallic fragments
• Cochlear implants
• Ferromagnetic implants
• Hydrocephaluspump
• Intra-utrine device (not all types)
• An iron wire behind the teeth
• Permanent make-up
• Tattoos above the shoulders (not all)- Specific contraindications to fMRI
• Seizure within prior year.
• Noncorrectable visual impairment.- MMSE < 19 points (measured at moment of
screening or at memory clinic with a maximum of 6 months in retrospect) (this
cutoff was also used in the Leiden 85-Plus study30)
- Severe physical restrictions (completely wheelchair dependent)
- Age above 90

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main study parameters/endpoints: 1) 3T MRI: the amplitude of the BOLD response<br /><br>in percentage signal change between stimulus on and off, time-to-peak response<br /><br>(sec), and time-to-baseline (sec) after discontinuation of the visual stimulus,<br /><br>classic signs of CAA (intracranial hemorrhage, lobar microbleeds,<br /><br>subarachnoidal hemorrhage and superficial siderosis) and SVD markers (number of<br /><br>small subcortical infarcts and lacunes, volume of white matter hyperintensities<br /><br>(WMHs), perivascular spaces in the basal ganglia and centrum semiovale, number<br /><br>and location of microbleeds and grey matter volume). 2) Neuropsychological<br /><br>assessment 3) Baseline characteristics, 4) DNA: APOE * genotype.</p><br>

Secondary Outcome Measures